Therapy-induced toxicity of the lungs: An overview

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 631-639

  Charpidou, Andriani G ^a   Gkiozos, Ioannis ^a   Tsimpoukis, Sotirios ^a   Apostolaki, Despoina ^a   Dilana, Kalliopi D ^a   Karapanagiotou, Eleni M ^a   Syrigos, Kostas N ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Antineoplastic drugs; Dyspnea; Interstitial lung disease; Lung injury; Pneumonitis; Pulmonary toxicity; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID;

ANGIOGENESIS; APOPTOSIS; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER PATIENT; CHEST TIGHTNESS; DYSPNEA; EARLY DIAGNOSIS; GENETIC PREDISPOSITION; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG CANCER; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG HEMORRHAGE; LUNG TOXICITY; NEUTROPENIA; PATHOGENESIS; PLEURA EFFUSION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; URTICARIA;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; LUNG DISEASES; RADIOTHERAPY;

EID: 61449266790     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Camus P, Foucher P, Bonniaud P and Ask K: Drug-induced infiltrative lung disease. Eur Resp J 18: 93-100, 2001.
2. Bardales RH, Xie SS, Schaefer RF and Hsu SM: Apoptosis is the major pathway responsible for the resolution of type II pneumocytes in acute lung injury. Am J Pathol 149: 845-852, 1996.
3. Polunovsky VA, Chen B, Henke C, Snover D, Wendt C, Ingbar DH and Bitterman PB: Role of mesenchymal cell death in lung remodeling after injury. J Clin Invest 92: 388-397, 1993.
4. Fehrenbach H: Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2: 33-46, 2001.
5. Camus P, Kudoh S and Ebina M: Interstitial lung disease associated with drug therapy. Br J Cancer 91: S18-S23, 2004.
6. Nagata S and Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
7. Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA and Liles WC: Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol 170: 6209-6216, 2003.
8. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, Kaneko Y and Kara N: Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J respire Cell Mol Biol 17: 272-278, 1997.
9. Hagimoto N, Kuwano K, Inosima I, Nakamura N, Fujita M, Maeyama T and Kara N: TGF-b1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol 168: 6470-6478, 2002.
10. Reed JC: Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ 13: 1378-1386, 2006.
11. Yoneda K: Distribution of proliferating-cell nuclear antigen and epidermal growth factor receptor in intraepithelial squamous cell lesions of human bronchus. Mod Pathol 7: 480-486, 1994.
12. Polosa R, Prosperini G, Leir SH, Holgate ST, Lackie PM and Davies DE: Expression of c-erB receptors and ligands in human bronchial mucosa. Am J Respir Cell Mol Biol 20: 914-923, 1999.
13. Aida S, Tamai S and Sekiguchi N: Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistocemical and immunoelectron-microscopic studies. Respiration 61: 161-166, 1994.
14. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL and Di Pietro LA: Vascular endothelial growth factor mediates angiogenic activity during proliferative phase of wound healing. Am J Pathol 152: 1445-1452, 1998.
15. Puddicomle SM, Polosa R, Richter A, Krishna MT, Howarth PH, Holgate ST and Davies DE: Involvement of the epithelial growth factor receptor in epithelial repair in asthma. FASEB J 14: 1362-1374, 2000.
16. Bussat S, Eddahibi S, Caste A, Fataccioli V, Gouge M, Housset B, Adnot S and Maitre B: Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 279: 371-378, 2000.
17. Trott KM, Herrmann T and Kasper M: Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys 58: 463-469, 2004.
18. Monson JM, Stark P, Reilly JJ, Sugarbaker DJ, Strauss GM, Swanson SJ, Decamp MM, Mentzer SJ and Baldini EH: Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 82: 842-850, 1998.
19. Bradley JD, Graham MV and Winter KW: Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small cell lung carcinoma. Int J Radiat Oncol Biol 61: 318-328, 2005.
20. Seppenwoolde Y, Lebesque JV, de Jaeger K, Belderbos JS, Boersma LJ, Schilstra C, Henning GT, Hayman JA, Martel MK and Ten Haken RK: Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 55: 724-735, 2003.
21. Chen Y, Williams J, Ding I, Hernade E, Liu W, Smudzin T, Finkelstein JN, Rubin P and Okuniff P: Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 12: 26-33, 2002.
22. Mauri D, Pentheroudakis G, Bafaloukos D, Samantas E, Syrigos KN, Kosmidis P, Fountzilas G and Pavlidis N: Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res 26: 3175-3181, 2006.
23. Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T, Nishikawa K and Ishihara H: Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonias. Lung Cancer 40: 79-84, 2003.
24. Dimopoulou I, Bamias A, Lyberopoulos P and Dimopoulos MA: Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17: 372-379, 2006.
25. Polyzos A, Syrigos KN, Stergiou J, Panopoulos C, Potamianou A, Vamvakas L and Georgoulias V: Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma. Cancer Chemother Pharmacol 55(5): 466-470, 2005.
26. Syrigos KN, Michalaki B, Alevyzaki F, Machairas A, Mandrekas D, Kindilidis K and Karatzas G: A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Res 22: 3583-3588, 2002.
27. Syrigos KN, Dannos I, Dionellis G, Bofos I, Alamara C, Dimakou E, Stratakos G and Papiris S: Biweekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study. Anticancer Res 25: 3489-3494, 2005.
28. Aamdal S, Wolff I, Kaplan S et al: Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 30A: 1061-1064, 1994.
29. Etienne B, Perol M, Nesme P, Vuillermoz S, Robinet G and Guerin JC: Acute diffuse interstitial pneumonopathy following docetaxel (Taxotere). Apropos of 2 cases. Rev Mal Respir 15: 199-203, 1998.
30. Merad M, Le Cesne A, Baldeyrou P et al: Docetaxel and interstitial pulmonary injury. Ann Oncol 8: 191-194, 1997.
31. Karacan O, Eyuboglu FO, Akcay S and Ozyilkan O: Acute interstitial pneumopathy associated with docetaxel hypersensitivity. Oncology 27: 563-565, 2004.
32. Wang CS, Yang KY and Pemg RP: Life-threatening hypersensitivity pneumonitis induced by docetaxel (Taxotere). Br J Cancer 85: 1247-1250, 2001.
33. Morris MJ, Santamauro J, Shia J Schwartz L, Vander Els N, Kelly K and Scher H: Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. Urology 60: 1111, 2002.
34. Reed WL, Mortimer JE and Picus J: Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94: 847-853, 2002.
35. Behrens RJ, Gulley JL and Dahut WL: Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther 10: 228-232, 2003.
36. Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakis J, Agelaki S, Malas K, Bozionelou V and Georgoulias V: High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 44: 363-368, 2004.
37. Dunsford ML, Mead GM, Bateman AC, Cook T and Tung K: Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 10: 943-947, 1999.
38. Syrigos KN, Karapanagiotou L, Charpidou A, Dilana K, Dannos I, Dionellis G, Rigopoulou A, Georgatou N and Roussos C: Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study. J Chemother 19(4): 438-443, 2007.
39. Semb KA, Aamdal S and Oian P: Capillary leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16: 3426-3432, 1998.
40. Bronstad A, Berg A and Reed RK: Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol 287: H963-968, 2004.
41. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A and Van Glabbeke M: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomised study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast cancer. J Clin Oncol 15: 3149-3155, 1998
42. Briasoulis E, Froudarakis M and Milionis HJ: Chemotherapy-induced non-cardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration 67: 680-683, 2000.
43. Aapro MS, Martin C and Hatty S: Gemcitabine - a safety review. Anticancer Drugs 9: 191-201, 1998.
44. Stathopoulos GP, Syrigos KN, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, Potamiannou A, Tsiakopoulos I, Androulakis N, Aravantinos G, Athanasiadis A, Papakotoulas P and Georgoulias V: Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 15: 224-229, 2004.
45. Angelaki S, Syrigos KN, Christophylakis C, Boukovinas I, Varthalitis J, Pavlakou G, Athanasiadis A, Kouroussis C, Vardakis N, Maltezakis G, Milaki G and Georgoulias V: A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small cell lung cancer. Oncology 66: 192-196, 2004.
46. Roychowdhury DF, Cassidy CA, Peterson P and Arning M: A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 20: 311-315, 2002.
47. Pavlakis N, Bell DR, Millward MJ and Levi JA: Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80: 286-291, 1997.
48. Vander Els NJ and Miller V: Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 114: 1779-1781, 1998.
49. Marruchella A, Fiorenzano G, Merizzi A, Rossi G and Chiodera PL: Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 11: 504-506, 1998.
50. Davidoff S, Shah RD and Arunabh T: Gemcitabine-induced respiratory failure associated with elevated erythrocyte sedimentation rate (ESR). Respir Med 100: 760-763, 2006
51. Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S and Mehrotra B: Gemcitabine-induced pulmonary toxicity. Case report and review of the literature. Am J Clin Oncol 25: 96-100, 2002.
52. Maas KW, van der Lee I, Bolt K, Zanen P, Lammers JW and Schramel FM: Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 41: 345-351, 2003.
53. Dimopoulou I, Efstathiou E, Samakovli A, Dafni U, Moulopoulos LA, Papadimitriou C, Limperopoulos P, Kastritis E, Roussos C and Dimopoulos MA: A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 15: 1250-1255, 2004.
54. Syrigos KN, Konstantinou M, Sepsas E, Papamichales G, Loulias A, Belenis I, Skottis I, Charpidou A and Roussos C: Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study. Anticancer Res 27(4C): 2887-2892, 2007.
55. Rowinsky EK and Donehower RC: Paclitaxel (Taxol). N Engl J Med 332: 1004-1014, 1995.
56. Gonzalez ID, Saez RS, Rodilla EM et al: Hypersensitivity reactions to chemotherapy drugs. Allergiol Immunol Clin 15: 161-181, 2000.
57. Bookman MA, Kloth DD, Kover PE, Smolinsky S and Drols RF: Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 8(6): 611-614, 1997.
58. Goldberg HL and Vannice SB: Pneumonitis related to treatment with paclitaxel. J Clin Oncol 13: 534-535, 1995.
59. Schweitzer VG, Juillard GJ, Bajada CL and Parker RG: Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 76: 1069-1072, 1995.
60. Wong P, Leung AN, Berry GJ, Atkins AK, Montoya GJ, Ruoss JS and Stockdale EF: Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. AJR Am J Roentgenol 176: 718-720, 2001.
61. Taniguchi N, Shinagawa N, Kinoshita I, Nasuhara Y, Yamazaki K, Yamagushi E, Akita H and Nishimura M: A case of paclitaxel-induced pneumonitis. Nihon Kokyuki Gakkai Zasshi 42: 158-163, 2004.
62. Fujimori K, Yokoyama A, Kurita Y, Uno K and Saijo N: Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 55: 340-344, 1998.
63. Ramanathan RK, Reddy VV, Holbert JM and Belani CP: Pulmonary infiltrates following administration of paclitaxel. Chest 110: 289-292, 1996.
64. Khan A, McNally D, Tutschka PJ and Bilgrami S: Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 31: 1471-1474, 1997.
65. Yamada K, Ikehara M, Tanaka G, Nomura I, Oshita F and Noda K: Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small cell lung cancer (JCOG 9807). Oncology 66: 94-100, 2004.
66. Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M and Havemann K: Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small cell lung cancer. J Clin Oncol 14: 1071-1076, 1996.
67. Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, Muller S and O'Byrne KJ: Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 36: 2329-2334, 2000.
68. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos KN, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G and Dimopoulos MA: Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Annal Oncol 19(1): 115-122, 2008.
69. Kudrik FJ, Rivera MP, Molina PL, Maygarden S and Socinski Ma: Hypersensitivity pneumonitis in advanced non-small cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and review of the literature. Clin Lung Cancer 4: 52-56, 2002.
70. Sotiriou C, van Houtte P and Klastresky J: Lung fibrosis induced by paclitaxel. Support Care Cancer 6: 68-71, 1998.
71. Robert F, Childs HA, Spencer SA, Redden DT and Hawkins MM: Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity. Semin Radiat Oncol 9(2 Suppl 1): 136-147, 1999.
72. Madarnas Y, Webster P, Shorter AM and Bjamason GA: Irinotecan-associated pulmonary toxicity. Anticancer Drugs 11: 709-713, 2000.
73. Yamada M, Kudoh S, Hirata K, Nakajima T and Yoshikawa J: Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 34: 71-75, 1998.
74. Souglakos J, Syrigos KN, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis Ch, Vardakis N, Christophilakis Ch, Kotsakis A and Georgoulias V: Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 15(8): 1204-1209, 2004.
75. Rothenberg ML, Eckardt JR, Kuhn JG et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128-1135, 1996.
76. Pilot HC, Wender DB, O'Connell MJ et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15: 2910-2919, 1997.
77. Michielin O, Udry E, Periard D et al: Irinotecan-induced interstitial pneumonia. Lancet Oncol 5: 322-324, 2004.
78. Fukuoka M, Niitani H, Suzuki A et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10: 16-20, 1992.
79. Masuda N, Fukuoka M, Kusunoki Y et al: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 10: 1225-1229, 1992.
80. Ohe Y, Yamamoto S, Suzuki K, Hojo F, Kakinuma R, Matsumoto T, Ohmatsu H and Nishiwaki Y: Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 37: 54-63, 2001.
81. Pectasides D, Samantas E, Fountzilas G, Briasoulis E, Kosmidis P, Skarlos D, Dimopoulos MA, Kalofonos HP, Economopoulos T and Syrigos KN: Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small cell lung cancer: a phase II study of the Hellenic Co-operative Oncology Group. Lung Cancer 58(3): 355-361, 2007.
82. Hirose T, Mizutani Y, Ohmori T, Ishida H, Hosaka T, Ando K, Shirai T, Okuda K, Ohnishi T, Horichi N, Kubota H and Adachi M: The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small cell lung cancer. Cancer Chemother Pharmacol 58(3): 361-367, 2006.
83. Gkiozos I, Charpidou A and Syrigos KN: Developments in the treatment of non-small cell lung cancer. Anticancer Res 27(4C): 2823-2827, 2007.
84. Allen AM, Czerminska M, JannePA, Sugarbaker DJ, Bueno R, Harris JR, Court L and Baldini EH: Fetal pneumonitis associated with intensity modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65: 640-645, 2006
85. Bozec A, Fischel JL and Milano G: Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol 18: 330-334, 2006.
86. Shepherd FA, Pareira JR, Cluleanu TE, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabábara P and Seymour L, for the National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353: 123-132, 2005.
87. Manegold C: Gefitinib (Iressa™ , ZD 1839) for non-small cell lung cancer (NSCLC): recent results and further strategies. Adv Exp Med Biol 532: 247-252, 2003.
88. Grinelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A and Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 12: 191-200, 2007.
89. Sandier A, Gray R, Perry MC, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
90. Evans TL: Highlights from the tenth conference on lung cancer. Oncologist 9: 232-238, 2004.
91. Genetech Pharmaceuticals Corporation: Tarceva (erlotinib) prescribing information. San Francisco, CA, pp. 1-2, 2004.
92. Sumpter K, Harper-Wynne C and O'Brien M: Acute lung injury as an adverse event of gefinitib. Lung Cancer 43: 367-368, 2004.
93. Danson S, Backhall F, Hulse P and Ransom M: Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 28: 103-113, 2005.
94. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E and Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22: 2184-2191, 2004.
95. Herbst RS and Sandler AB: Non-small cell lung cancer and antiongiogenetic therapy: what can be expected of bevacizumab? Oncologist 9: 19-26, 2004.
96. Polyzos A, Tsavaris N, Kosmas C, Gogas H, Vadiaka M, Markopoulos C, Giannopoulos A, Kalahanis N, Stamatiadis D, Kouraklis G, Karatzas G, Liapis C and Syrigos KN: Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Anticancer Res 23(3C): 2917-2923, 2003.
97. Azoulay E, Attalah H, Harf A, Schlemmer B and Delclaux C: Granulocyte colony-stimulating factor on neutrophil-induced pulmonary toxicity: myth or reality? Chest 120: 1695-1701, 2001.
98. Hassaballa HA, Cohen ES, Khan AJ, Ali A, Bonomi P and Rubin D: Positron-emission tomography demostrates radiation-indused changes to non-radiated lungs in lung cancer patients treated with radiation and chemotherapy. Chest 128: 1448-1452, 2005.
99. Walgren RA, Meucci MA and McLeod HL: Pharmacogenomic discovery approaches: will the real gene stand up? J Clin Oncol 23: 7342-7349, 2005.